CNBC April 26, 2024
Annika Kim Constantino

Key Points

– The Food and Drug Administration approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first gene therapy to win clearance in the U.S.

– The agency greenlighted the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B.

– Pfizer said the treatment will be available by prescription to eligible patients this quarter and has a hefty $3.5 million price tag before insurance and other rebates.

The Food and Drug Administration on Friday announced that the agency approved Pfizer‘s treatment for a rare genetic bleeding disorder, making it the company’s first gene therapy to win clearance in the U.S.

The agency greenlighted the drug, which...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Related Articles:
Apple Watch's AFib detection tool earns landmark FDA approval
FDA flags 10 observations in another Form 483 for a Zydus plant
FDA targets cancer drugs to be less toxic, more cost effective
FDA Finalizes Rule to Phase Out Enforcement Discretion of Laboratory-Developed Tests
Apple Watch's AFib-tracking app certified by FDA for use in clinical studies

Share This Article